Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume 29, Issue 12, Pages 2324-2335
Publisher
American Association for Cancer Research (AACR)
Online
2023-03-20
DOI
10.1158/1078-0432.ccr-22-1305
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- (2021) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
- (2021) Jamie M. Sperger et al. JOURNAL OF CLINICAL ONCOLOGY
- Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
- (2021) James T. Coates et al. Cancer Discovery
- Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer
- (2021) Rahul Aggarwal et al. JAMA Oncology
- Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
- (2020) Yingming Li et al. CLINICAL CANCER RESEARCH
- The DNA methylation landscape of advanced prostate cancer
- (2020) Shuang G. Zhao et al. NATURE GENETICS
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
- (2019) William S. Chen et al. EUROPEAN UROLOGY
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
- (2018) John K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
- (2017) Dawei Jiang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation
- (2016) Jamie M. Sperger et al. CLINICAL CANCER RESEARCH
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
- (2016) Christine Henzler et al. Nature Communications
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Targeting CD146 with a64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas
- (2015) Yunan Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
- (2015) Marco Trerotola et al. Oncotarget
- The detection of EpCAM+ and EpCAM– circulating tumor cells
- (2015) Sanne de Wit et al. Scientific Reports
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- (2014) Dana E. Rathkopf et al. EUROPEAN UROLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trop-2 Promotes Prostate Cancer Metastasis By Modulating 1 Integrin Functions
- (2013) M. Trerotola et al. CANCER RESEARCH
- Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis
- (2012) Marco Trerotola et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now